Oncurious Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
2ndary - Private
- Investors
-
2
Oncurious General Information
Description
Developer of innovative oncology treatments designed to enhance T-cell migration, infiltration, and activity into resistant tumor sites. The company's treatment focuses on clinical development activities in orphan pediatric oncology treatment, with a focus on preclinical research and drug development programs, and also works on therapies that are focused on the elimination of CCR8-expressing immune-suppressive regulatory T cells with the aim of boosting the anti-tumor immune response, enabling the healthcare industry to receive new approaches for immuno-oncology drugs targeting a broad spectrum of cancers.
Contact Information
Website
www.oncurious.comCorporate Office
- Gaston Geenslaan 1
- 3001 Leuven
- Belgium
Corporate Office
- Gaston Geenslaan 1
- 3001 Leuven
- Belgium
Oncurious Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | 01-Dec-2025 | Completed | Pre-Clinical Trials | |||
| 3. Grant | 11-Jun-2019 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC | 12-Dec-2017 | $3.54M | $3.54M | Completed | Pre-Clinical Trials | |
| 1. Joint Venture | 14-Apr-2015 | Completed | Pre-Clinical Trials |
Oncurious Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Pref | ||||||||
| Pref | ||||||||
| Pref | 125 | $1181.55 | $1181.55 | 1x | $1181.55 | 2.33% |
Oncurious Patents
Oncurious Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022136647-A1 | Human ccr8 binders | Inactive | 24-Dec-2020 | ||
| WO-2022136650-A1 | Murine cross-reactive human ccr8 binders | Inactive | 24-Dec-2020 | ||
| WO-2022136649-A1 | Non-blocking human ccr8 binders | Inactive | 24-Dec-2020 | ||
| WO-2022117569-A1 | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer | Inactive | 02-Dec-2020 | ||
| WO-2022117572-A2 | An ltbr agonist in combination therapy against cancer | Inactive | 02-Dec-2020 | C07K16/2866 |
Oncurious Signals
Oncurious Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| VLAIO | Limited Partner | |||
| Oxurion | Holding Company | Majority |
Oncurious FAQs
-
When was Oncurious founded?
Oncurious was founded in 2015.
-
Where is Oncurious headquartered?
Oncurious is headquartered in Leuven, Belgium.
-
What is the size of Oncurious?
Oncurious has 3 total employees.
-
What industry is Oncurious in?
Oncurious’s primary industry is Drug Discovery.
-
Is Oncurious a private or public company?
Oncurious is a Private company.
-
What is Oncurious’s current revenue?
The current revenue for Oncurious is .
-
How much funding has Oncurious raised over time?
Oncurious has raised $3.54M.
-
Who are Oncurious’s investors?
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process